MedPath

Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears

Not Applicable
Completed
Conditions
Dry Eye Syndrome
Interventions
Other: TheraTears lubricating drops
Registration Number
NCT02100787
Lead Sponsor
Jenkins Eye Care
Brief Summary

The objective of the study is to see if there is a change in tear osmolarity over time when moderate to severe dry eye subjects are treated with TheraTears® lubricating drops.

Detailed Description

The hypothesis is that the measured tear osmolarity from study participants decrease with sustained use of a over-the-counter artificial tears, TheraTears® lubricating drops, over an eight week period. Participant's dry eye symptoms would also improve with sustained use of TheraTears® lubricating drops.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18
Inclusion Criteria
  1. Is at least 21 years of age and has full legal capacity to volunteer;
  2. Has read and signed the information consent letter;
  3. Is willing and able to follow instructions and maintain the appointment schedule;
  4. Is diagnosed with dry eye syndrome (in at least one eye), indicated by current ocular examination, prior history (self-reported history of dry eye is acceptable) and current use of treatments for dry eye;
  5. Has a minimum osmolarity reading of 316 mosm/kg at the baseline visit in at least one eye.
Exclusion Criteria
  1. Has taken part in another research study within the last 30 days;
  2. Planned contact lens wear during the course of the study;
  3. Staff at the investigational site or family member of site staff or family member of currently enrolled participant;
  4. Any subject that violates the washout period by using eye drops during the 72hrs washout period;
  5. Has any known ocular disease including active ocular infection, inflammation or allergy, especially Salzmann's nodular degeneration, symptomatic conjunctivochalasis, and fixation disparity syndrome;
  6. Used Restasis (or similar topical medication) within the last 6 months;
  7. Has a systemic condition that in the opinion of the investigator may affect the dry eye status of the subject, especially those newly diagnosed, newly prescribed and/or unstable;
  8. Is pregnant, lactating or planning a pregnancy at the time of enrolment (verbal confirmation necessary);
  9. Use of medications such as: Systemic Antihistamine (e.g., Allegra®, Benadryl®, Claritin®, Dimetapp®, Unisom®, Zyrtec®, etc.), Isotretinoin (e.g., Accutane®, Roaccutane®, Amnesteem®, Claravis®, Isotroin®, Sotret®) or similar medications;
  10. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
  11. Has undergone ocular surgery(LASIK, Cataract, etc)within the last year.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
TheraTears lubricating dropsTheraTears lubricating dropsTheraTears lubricating eye drops to be used 1 drop in both eyes four times a day (QID)
Primary Outcome Measures
NameTimeMethod
Change in the Ocular Surface Disease Index (OSDI) scoreBaseline and 8 weeks

The OSDI is a questionnaire that the subject completes to gauge their dry eye symptoms.

Change in tear osmolarityBaseline and 8 weeks
Secondary Outcome Measures
NameTimeMethod
Change in visual acuityBaseline and 8 weeks
Change in Tear Break Up Timebaseline and 8 weeks
Change in Phenol Red Thread testbaseline and 8 weeks
Change in corneal and conjunctival stainingbaseline and 8 weeks

Trial Locations

Locations (1)

Jenkins Eye Care

🇺🇸

Honolulu, Hawaii, United States

© Copyright 2025. All Rights Reserved by MedPath